New AP Report Shows WHO Actively Covered Up China’s Lies

Follow us on social media

Millions around the world have pondered how the #WHO could have possibly been so completely duped by #Beijing during the early days of the outbreak in January, when the organization parroted lies about the virus and praised Beijing as a “model” of pandemic response. Prior reports by the Associated Press and other Western media organizations have exposed how Beijing withheld critical information about the virus (including evidence of human-to-human spread) for days while #China gobbled up all the PPE and other critical medical supplies.

On Tuesday, as the US heals from a long weekend of violence and unrest, the AP has published a new report based on the details of a never-before-reported internal call where WHO higher-ups discussed what to do about China’s obstinance, fearing a re-run of SARS. The recording reveals that Beijing didn’t immediately cooperate with the WHO, as the WHO had previously claimed, but instead dragged its feet, much to the consternation of several top officials at the UN-linked NGO.

Not only did the CCP deliberately suppress critical info about the outbreak in #Wuhan (identities and other patient-related data), but Beijing also withheld a map of the virus’s genome for roughly a week after researchers finished mapping it, among other transgressions (Remember when the WHO praised China’s decision to swiftly map and share the virus genome as unassailable evidence that Beijing cares about accountability?) When China finally released the information to the WHO, they apparently only did so because a team of Chinese researchers had shared the information with another third party.

Throughout January, the #WorldHealthOrganization publicly praised China for what it called a speedy response to the new #coronavirus. It repeatedly thanked the #Chinese government for sharing the genetic map of the virus “immediately,” and said its work and commitment to transparency were “very impressive, and beyond words.”

But behind the scenes, it was a much different story, one of significant delays by China and considerable frustration among WHO officials over not getting the information they needed to fight the spread of the deadly virus, The Associated Press has found.

Despite the plaudits, China in fact sat on releasing the genetic map, or genome, of the virus for more than a week after three different government labs had fully decoded the information. Tight controls on information and competition within the Chinese public health system were to blame, according to dozens of interviews and internal documents.

Chinese government labs only released the genome after another lab published it ahead of authorities on a virologist website on Jan. 11. Even then, China stalled for at least two weeks more on providing WHO with detailed data on patients and cases, according to recordings of internal meetings held by the U.N. health agency through January — all at a time when the outbreak arguably might have been dramatically slowed.

In fact, the WHO’s congratulatory approach during the early days of the outbreak was part of a strategy to coax more information out of the government in Beijing. During transcripts of the call, American staffers at the WHO (the likely source of these leaks) complained that Beijing was giving them information “15 minutes before it appears on CCTV.”

WHO officials were lauding China in public because they wanted to coax more information out of the government, the recordings obtained by the AP suggest. Privately, they complained in meetings the week of Jan. 6 that China was not sharing enough data to assess how effectively the virus spread between people or what risk it posed to the rest of the world, costing valuable time. “We’re going on very minimal information,” said American epidemiologist Maria Van Kerkhove, now WHO’s technical lead for COVID-19, in one internal meeting. “It’s clearly not enough for you to do proper planning.” “We’re currently at the stage where yes, they’re giving it to us 15 minutes before it appears on CCTV,” said WHO’s top official in China, Dr. Gauden Galea, referring to the state-owned China Central Television, in another meeting.

The story behind the early response to the virus comes at a time when the U.N. health agency is under siege, and has agreed to an independent probe of how the pandemic was handled globally. After repeatedly praising the Chinese response early on, U.S. President Donald Trump has blasted WHO in recent weeks for allegedly colluding with China to hide the extent of the coronavirus crisis. He cut ties with the organization on Friday, jeopardizing the approximately $450 million the U.S. gives every year as WHO’s biggest single donor.

Perhaps the most interesting segment of the AP’s reporting came two seconds before the agency appeared to dismiss the fact that China’s prevarications during the early days of the virus violated international law (it’s okay since the WHO has no enforcement powers).

At one point, the AP insisted, apropos of nothing, that the leaked transcript doesn’t support “either the US or China”, but merely offers a picture of an organization in turmoil. Somehow, we doubt this disclaimer will dissuade Trump and the China hawks in his administration from citing the report as just the latest evidence justifying their suspicions of Beijing.

The new information does not support the narrative of either the U.S. or China, but instead portrays an agency now stuck in the middle that was urgently trying to solicit more data despite limits to its own authority. Although international law obliges countries to report information to WHO that could have an impact on public health, the U.N. agency has no enforcement powers and cannot independently investigate epidemics within countries. Instead, it must rely on the cooperation of member states.

WHO staffers debated how to press China for gene sequences and detailed patient data without angering authorities, worried about losing access and getting Chinese scientists into trouble. Under international law, WHO is required to quickly share information and alerts with member countries about an evolving crisis. Galea noted WHO could not indulge China’s wish to sign off on information before telling other countries because “that is not respectful of our responsibilities.” After all, while we might not possess any direct evidence that the novel coronavirus leaked from a biolab in Wuhan, it’s now become abundantly cleared that Beijing lied, and people died, and the WHO failed in its mission to safeguard the public health of the most vulnerable nations.

Related Articles

COVID Reference

Six weeks after the third edition, the world has changed again.
The pandemic is raging in South America, particularly in Brazil,
Ecuador and Peru. SARS-CoV-2 is under control in China, but in
Iran it is not. And in Europe, where most countries have weathered
the first wave and open borders to save a compromised tourist season, is now wondering if and for how long this biological
drôle de guerre could last.

Science has moved ahead, too. We have seen a more complex
picture of COVID-19 and new clinical syndromes; the first data
from vaccine trials; first results from randomized controlled
drug studies; encouraging publications on monoclonal neutralizing antibodies and serological evidence about the number of people who have come into contact with SARS-CoV-2. Unfortunately, we have also seen the first science scandal with fake data published in highly ranked journals. And we face new challenges like long-term effects of COVID-19 and a Kawasaki-like inflammatory multisystem syndrome in children.

For quite some time, prevention will continue to be the primary
pillar of pandemic control. In future waves of the SARS-CoV-2
pandemic, we will focus on the conditions under which SARSCoV-
2 is best transmitted: crowded, closed (and noisy) places and
spaces. Although hospitals are not noisy, they are crowded and
closed, and the battle against the new coronavirus will be decided
at the very center of our healthcare system. Over the next
months and maybe years, one of all of our top priorities will be
to give all healthcare workers and patients perfect personal protective equipment.

The HPV Vaccine: An Ethical Dilemma

In 2014 there were numerous reports of mass hysteria and mystery illnesses spreading around the small town of El Carmen De Bolivar, Colombia. According to an article published by CBS, there was a steady increase of young women being hospitalized in this small town, all of which reported the same symptoms of fainting, numbness and tingling of the hands and feet, and headaches. Speculations about the Gardasil vaccination arose, but were disregarded by the mayor of the town stating that “there is no evidence the vaccine, which has undergone extensive testing and regulation is to blame” (CBS, 2014). According to this statement, he is not necessarily wrong, because the clinical trials of this vaccine have been proven to have misleading conclusions due to errors in the study design.

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID- 19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Despite our small number of cases, the potential of HCQ in the treatment of COVID-19 has been partially confirmed. Considering that there is no better option at present, it is a promising practice to apply HCQ to COVID-19 under reasonable management. However, Large-scale clinical and basic research is still needed to clarify its specific mechanism and to continuously optimize the treatment plan.

Responses